Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study-Reference-Cited by-同舟云学术

Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study

Published:2022-05-11 Issue:7 Volume:39 Page:3146-3158
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Cornberg Markus^ORCID,Ahumada Adriana,Aghemo Alessio,Andreoni Massimo,Bhagat Abhi,Butrymowicz Isabel,Carmiel Michal,Chodick Gabriel,Conway Brian,Song Yanna,Gasbarrini Antonio,Hüppe Dietrich,Plaza Francisco Jorquera,Lampertico Pietro,Alonso Maria Luisa Manzano,Myles Lindsay,Persico Marcello,Ramji Alnoor,Sarrazin Christoph,Villa Erica,Weil Clara,Otano Juan Isidro Uriz,

Funder

AbbVie

Medizinische Hochschule Hannover (MHH)

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-022-02158-6.pdf

Reference17 articles.

1. World Health Organization (WHO). Hepatitis C fact sheet. 2021. https://www.who.int/news-room/fact-sheets/detail/hepatitis-c. Cited 04 Oct 2021

2. Polaris Observatory, H. C. V. Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2015;2017(2):161–76.

3. Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet. 2015;385:1124–35.

4. Kronenberger B, Zeuzem S. Current and future treatment options for HCV. Ann Hepatol. 2009;8:103–12.

5. European Association for the Study of the Liver, Clinical Practice Guidelines Panel Chair, EASL Governing Board representative, Panel members. EASL recommendations on treatment of hepatitis C: Final update of the series. J Hepatol. 2020;73:1170–218.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SASLT guidelines: Update in treatment of hepatitis C virus infection, 2024;Saudi Journal of Gastroenterology;2024-01

2. Assessment of Drug–Drug Interaction Risk Between Intravenous Fentanyl and the Glecaprevir/Pibrentasvir Combination Regimen in Hepatitis C Patients Using Physiologically Based Pharmacokinetic Modeling and Simulations;Infectious Diseases and Therapy;2023-07-20

3. Glecaprevir/Pibrentasvir is safe and effective in Italian patients with chronic hepatitis C aged 75 years or older: A multicentre study;Liver International;2023-04-30

4. Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry;Hepatology International;2023-03-27